FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
lorlatinib Sensitive: C4 – Case Studies
|
lorlatinib Sensitive: C4 – Case Studies
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
alectinib Sensitive: C4 – Case Studies
|
alectinib Sensitive: C4 – Case Studies
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
crizotinib Resistant: C4 – Case Studies
|
crizotinib Resistant: C4 – Case Studies
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
pazopanib Resistant: C4 – Case Studies
|
pazopanib Resistant: C4 – Case Studies
|